Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Extavia

Novartis day

Novartis licenses Ophthotech eye drug in $1bn deal

Fovista is a potential first-in-class treatment for wet AMD

Novartis building

FDA rejects Novartis’ breakthrough heart failure drug

Regulator wants more data on serelaxin

- PMLiVE

Invokana set for NICE recommendation

Janssen drug will provide another treatment option in diabetes

Bayer symbol

J&J and Bayer unveil new bioincubators

Major pharma companies look to improve collaboration with start-ups

- PMLiVE

NICE won’t back early use of Zytiga in prostate cancer

Says Janssen drug should not be used prior to chemotherapy

National Institute for Health and Care Excellence NICE logo

NICE backtracks on prostate cancer drug enzalutamide

Says Astellas and Medivation's Xtandi can be used within the NHS in England and Wales

Novartis building

Novartis plans filings for acromegaly candidate

Could add to Signifor’s indications

- PMLiVE

Bayer buys Merck consumer health unit

Continues trend for major pharma deals

- PMLiVE

Bayer outlines some of its digital health needs

Wants to work with startups in areas such as oncology and men's health

- PMLiVE

Novartis teams up with artist in meningitis campaign

Digital book contains photos of disease survivors taken by Anne Geddes

Novartis building

Novartis gets US nod for lung cancer relapse therapy Zykadia

Second ALK inhibitor to be approved after Pfizer’s Xalkori

- PMLiVE

New Novartis MS app will turn up the heat on its rivals

Patients can use SymTrac iPhone app to track symptoms and relapses on their current treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links